DFX Intelligence

Data Factory

Visen Pharmaceuticals

维昇药业是专注于内分泌相关治疗领域的创新型生物医药公司，致力于以更具人性关怀的创新疗法，让内分泌患者享有更好的治疗过程与疗效，以实现向往的生活。维昇以患者需求为先，致力于提供同类首创（First in Class）或同类最优（Best in Class）的内分泌疾病产品和治疗方案

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:030892f8-a177-4c07-8e17-434f8509b884

Data as of Sep 16, 2026 (this record's last observation) from Sworn filings; Announcements; Limited partners. Page built Sep 21, 2026, 7:29 PM UTC and rebuilt at most every 15 minutes.

Relationships: 1
Dated events: 0
On other graphs: 2
Observed: Sep 16, 2026 to Sep 16, 2026
4 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

Visen Pharmaceuticals

Portfolio company · cited

Private Equityidentity

Visen Pharmaceuticals

Portfolio company · cited

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Rounds: 0
Investors: 1
People: 0
Website: visenpharma.com

Investors

Investor	Class	Fund	Partner	Role	Attribution
Vivo Capital, LLC	Multi stage VC	n/a	n/a	unknown	Unknown

Relationships

Invested in (1)

← Vivo Capital, LLCFirmPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site

Dated events

No dated event names this entity yet.

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:030892f8-a177-4c07-8e17-434f8509b884
First observed: Sep 16, 2026
Last observed: Sep 16, 2026 5 days ago
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.